QIAGEN

QIAGEN NV is a provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The firm automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D, and industrial applications, primarily forensics). The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

QIAGEN surpasses 2022 targets, eyes growth in diagnostics and biopharma

QIAGEN's strong performance in 2022 exceeded expectations, supported by robust financials and strategic acquisitions.
Despite market challenges, the company remains confident in achieving its 2023 targets, focusing on growth opportunities in diagnostics and biopharma.
Emphasis on innovation, customer knowledge, and strategic shifts position QIAGEN well for sustained growth and leadership in the industry.

QIAGEN surpasses Q1 sales targets, eyes China growth opportunities

QIAGEN's Q1 2023 performance exceeded expectations, with strong sales growth and margin improvements.
The company remains focused on driving growth through product innovation and strategic market expansion.
Challenges include cautious customer spending and evolving market dynamics, particularly in China.
Opportunities lie in capitalizing on strong product performance, investing in new solutions, and expanding market reach.

QIAGEN reports strong Q2 earnings, eyes China growth opportunities

QIAGEN's Q2 performance was solid, driven by key growth areas, but challenges persist with net sales decline and market volatility. The company's strengths in base business sales and focus on growth pillars position it well for future opportunities in China and market expansion.

QIAGEN surpasses Q3 expectations, focuses on sustained growth strategies

QIAGEN's Q3 2023 performance exceeded expectations, showcasing strong financials and strategic leadership changes, with a reaffirmed full-year outlook for 2023.
The company's strengths lie in successful product pillars, sustained growth strategies, and a strategic focus on non-COVID products in key markets.
Challenges include debt repayment impacts, external market uncertainties, and competitive differentiation in expanding product offerings, while opportunities exist in market expansion, innovation, and automation investments.

QIAGEN surpasses Q4 expectations, eyes strategic growth opportunities

QIAGEN's Q4 performance exceeded expectations, showcasing strong growth and profitability.
Challenges include potential risks in Q1 and delays impacting certain product growth.
Strategic investments and upcoming launches present opportunities for continued growth and market expansion.
Overall, QIAGEN's focus on innovation and strategic acquisitions positions them for sustained success in the future.

QIAGEN beats Q1 sales targets, eyes FDA approvals for growth

QIAGEN's Q1 2024 performance exceeded expectations, with strong sales in Diagnostic Solutions. The company reaffirmed its full-year outlook and highlighted advancements in its product portfolio. Despite challenges in the Chinese market, QIAGEN remains focused on growth opportunities and efficient capital allocation.

QIAGEN surpasses Q3 expectations, boosts outlook amid leadership change

QIAGEN delivered strong Q3 results, surpassing expectations and demonstrating improved profitability. Despite leadership changes, the company's strategic initiatives and global positioning bode well for future growth and resilience in the face of market dynamics.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Investors are wondering whether to welcome or fear Qiagen’s recent announcement about its CEO’s departure, slowing sales, and business restructuring.

Is Qiagen’s Stumble An Opportunity For Investors?

Ambarella

SmileDirectClub

Even kind words from Wall Street pros aren't always enough to lift a stock.

Why Ambarella, Qiagen, and SmileDirectClub Slumped Today

A trio of news items has the healthcare company in transition.

Here's Why Qiagen Plummeted Today

Qiagen stock crashed to a three-year low Tuesday after the DNA testing company preannounced disappointing third-quarter results and the exit of its Chief Executive, Peer Schatz.

DNA Testing Stock Plunges To 3-Year Low On Lame Third-Quarter View

Qiagen NV (NYSE: QGEN) shares were coming under intense selling pressure Tuesday following a trio of announcements from the company.

Qiagen Shares Tumbles Following Q3 Sales Warning, Sudden CEO Departure

Qiagen QIA, -16.74% shares stumbled 17% as the diagnostics firm said third-quarter sales at constant exchange rates will grow 3% instead of the previous estimate of 4% to 5% growth.

Qiagen shares stumble on sales warning, CEO departure

Poor QuantiFERON-TB sales in Americas and an unfavourable currency translation affect QIAGEN's (QGEN) overall performance.

QIAGEN (QGEN) Hurt by Low QuantiFERON-TB Sales & FX Headwind

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?

Qiagen (QGEN) Down 8.7% Since Last Earnings Report: Can It Rebound?

The study outcome has been a major step for QIAGEN (QGEN) toward offering accurate diagnosis and treatment of gastroenteritis.

QIAGEN Posts QIAstat-Dx Gastrointestinal Panel Study Results

Qiagen Slips Up but Is Far From Broken

Qiagen NV (QGEN) CEO Peer Schatz on Q2 2019 Results - Earnings Call Transcript

QIAGEN (QGEN) registers revenue growth across majority of its geographies in Q2.

QIAGEN (QGEN) Misses Q2 Earnings Estimates, Lowers View

Qiagen (QGEN) delivered earnings and revenue surprises of -2.94% and -1.24%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) Q2 Earnings and Revenues Miss Estimates

Bruker

Cerner

McKesson

The distribution agreement will enable QIAGEN (QGEN) to expand reach in the healthcare market.

QIAGEN Inks Distribution Deal With Mckesson Medical-Surgical

QIAGEN (QGEN) expects multi-site clinical validations for this new system during 2020 Lyme disease season.

QIAGEN-DiaSorin Union to Enhance QuantFERON for Lyme Disease

Qiagen (QGEN) Up 4% Since Last Earnings Report: Can It Continue?

QIAGEN's (QGEN) therascreen PIK3CA Kit is the first companion diagnostic test to have attained premarket approval from the FDA.

QIAGEN (QGEN) Launches PIK3CA Kit for Breast Cancer Patients

This acclaim marks a giant leap for QIAGEN (QGEN) in the field of tuberculosis diagnosis.

QIAGEN (QGEN) to Win U. N. Accolade for QuantiFERON-TB Access

Qiagen NV (NYSE: QGEN) shares were spiking higher Monday following the announcement of FDA approval for its molecular diagnostic testing system.

Qiagen Snags FDA Nod For Molecular Diagnostic System, Announces US Launch

Inovio Pharmaceuticals

QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.

QIAGEN Partners Inovio to Develop Companion Diagnostics

The QIAstat should accelerate growth for the diagnostic testing company.

Qiagen Looks to Growth in the Second Half of the Year

Qiagen NV (QGEN) CEO Peer Schatz on Q1 2019 Results - Earnings Call Transcript

QIAGEN (QGEN) sees year-over-year growth across all segments and majority of geographies.

QIAGEN's (QGEN) Q1 Earnings Top Estimates, Revenues Miss

Qiagen (QGEN) delivered earnings and revenue surprises of 3.85% and -0.76%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) Tops Q1 Earnings Estimates

QIAGEN (QGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

News for QIAGEN Stock (QGEN)